Kevin Thornal will try to lead rapidly growing spinal cord stimulation (SCS) company Nevro to profitability as its new CEO.
Thornal will take over as CEO and president on 24 April, the company announced on 19 April. Current CEO and...
Nevro Names Kevin Thornal As Its New CEO; Investors Remain Disappointed In Results
Thornal will replace Keith Grossman who is retiring. Investors and analysts hope Thornal will help the spinal cord stimulation company reach profitability by growing its “core” chronic pain business.
More from Leadership
• By
The pulsed-field ablation market is surging, with the UK NHS opening doors and FDA updates for major players. Medtech Insight spoke with Steven Mickelsen, founder of Farapulse (the first clinically approved PFA system), about the sector's growth and his new venture, Field Medical.
• By
Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.
• By
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
• By
Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.
More from Medtech Insight
• By
Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.
• By
MedTech Europe wants the EU to continue its commitment to reach a negotiated tariff solution with the US and measured restraint amid escalating trade tensions.
• By
The European Commission is focusing on how tiny particles behave to help create an EU industrial “powerhouse.”